Navigation Links
Senetek PLC Reports First Quarter 2009 Financial Results
Date:5/15/2009

NAPA, Calif., May 15 /PRNewswire-FirstCall/ -- Senetek PLC (OTC Bulletin Board: SNKTY), a Life Sciences company engaged in the development of technologies that target the science of healthy aging, announced results for the quarter ended March 31, 2009.

Revenue for the quarter ended March 31, 2009 was $461,000, compared with $230,000 reported in the fourth quarter of 2008 and $441,000 reported in the first quarter of 2008.

Revenues from Pyratine product sales in the first quarter of 2009 were $93,000 compared to $43,000 and $89,000 in the fourth quarter of 2008 and the first quarter of 2008, respectively. Pyratine XR(TM), launched in March 2009 made a limited contribution to first quarter 2009 sales due to the timing of the product launch.

Royalty revenue on sales of monoclonal antibodies totaled $323,000 in the first quarter of 2009 compared to $145,000 and $279,000 in the fourth quarter of 2008 and the first quarter of 2008, respectively.

Revenues in the first quarter of 2008 included $30,000 in product sales of Kinetin raw material and formulated products. Other quarterly sources of revenues were comparable between the first quarter of 2009 and the fourth and first quarters of 2008.

Net loss for the quarter ended March 31, 2009 totaled $1,147,000 or $0.15 per diluted share compared to a net loss of $1,209,000 or $0.16 per diluted share for the quarter ended December 31, 2008 and a net loss of $1,757,000 or $0.23 per diluted share for the quarter ended March 31, 2008.

In March, the Company launched Pyratine XR(TM) at the 67th Annual Meeting of the American Academy of Dermatology. In one rosacea specific study performed at the University of California, Irvine, data demonstrated that Pyratine XR(TM) showed continual improvement for all of the major symptoms of rosacea - redness, lesions and spider veins - throughout the entire course of a 48 week treatment period. This suggests that Pyratine XR(TM) may offer important advantages over currently available treatments for rosacea, many of which have issues with long-term tolerability. Since rosacea is a chronic condition that often requires extended treatment periods with topical agents that can cause high skin sensitivity, treatments that provide sustained relief of the signs and symptoms of rosacea are needed.

About Senetek PLC:

Senetek PLC (OTCBB:SNKTY) is a life sciences company engaged in the development of breakthrough technologies that target the science of healthy aging. The company's extensive research collaborations have resulted in a strong pipeline of patented compounds and products with broad therapeutic applications and a leading presence in dermatology. Senetek collaborates with established specialty pharmaceutical companies in the final development and marketing of its proprietary products, most recently resulting in the development of kinetin, the best-selling anti-aging product sold in the North American physician market. For more information, visit the company's websites www.senetekplc.com

www.pyratine-6.com

www.pyratinexr.com

This news release contains statements that may be considered 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act. Forward-looking statements by their nature involve substantial uncertainty, and actual results may differ materially from those that might be suggested by such statements. Important factors identified by the Company that it believes could result in such material differences are described in the Company's Annual Report on Form 10-K for the year 2008. However, the Company necessarily can give no assurance that it has identified or will identify all of the factors that may result in any particular forward-looking statement materially differing from actual results, and the Company assumes no obligation to correct or update any forward-looking statements which may prove to be inaccurate, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Senetek PLC
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Senetek PLC Reports 2008 Financial Results
2. Dynamics Group AG Publishes Research Report on Senetek
3. Senetek Announces Termination of Invicorp(R) License Agreement With Ardana Bioscience Limited
4. Senetek Announces Plan for Promotion, Sales and Distribution of Pyratine-6(TM)
5. Senetek PLC Resolves Dispute With Marketer of Pyratine-6(TM) on Most Favorable Terms
6. Senetek PLC Announces Key Personnel Appointments
7. Senetek PLC Reports 2007 Financial Results
8. Senetek PLC Announces North American Partner for Invicorp(R) Secures Financing for Advancement of Marketing and Development Efforts
9. Senetek PLC Announces Launch of New Website
10. Senetek PLC Announces Debut of Pyratine-6(TM) at the Annual Meeting of the American Academy of Dermatology
11. Senetek PLC Reports Third Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... Viejo, California (PRWEB) , ... June 27, 2016 , ... ... are fully customizable inside of Final Cut Pro X," said Christina Austin - CEO ... another unique style. Final Cut Pro X users can now reveal the ...
(Date:6/27/2016)... ... June 27, 2016 , ... ... strategic partnership with Connance, a healthcare industry leader providing predictive analytics to ... technology combine to provide health systems, hospitals and ambulatory surgical centers with ...
(Date:6/27/2016)... Overland Park, KS (PRWEB) , ... June 27, 2016 , ... ... leader in retailers of Eyeglasses . , Millions of individuals in the United ... life, eyeglasses have become a way to both correct vision and make a fashion ...
(Date:6/26/2016)... ... 26, 2016 , ... On June 10-11, 2016, A Forever Recovery, a holistic ... World’s Longest Breakfast Table in Battle Creek, MI, where the rehabilitation facility is located. ... some of the world’s leading providers of cereal and other breakfast foods. Its residents ...
(Date:6/26/2016)... ... June 26, 2016 , ... PawPaws brand pet supplements ... that was developed to enhance the health of felines. The formula is all-natural and ... main herbs in the PawPaws Cat Kidney Support Supplement Soft Chews are ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) ... Improvements Act of 1976, as amended ("HSR"), with respect ... Nasdaq: CPXX ) expired effective June 24, ... As previously announced on May 31, 2016, Jazz Pharmaceuticals ... which Jazz Pharmaceuticals has commenced a tender offer for ...
(Date:6/24/2016)... HILL, N.C. , June 24, 2016 /PRNewswire/ ... healthcare decisions and regulators/payers have placed more emphasis ... new environment, patient support programs in the pharmaceutical ... for patients, medications. Consequently, pharmaceutical companies are focusing ... ensure they are providing products and services that ...
(Date:6/24/2016)... CAMBRIDGE, Mass. , June 24, 2016 /PRNewswire/ ... the Spaulding Rehabilitation Network,s Dean Center for ... of Physical Medicine and Rehabilitation, MIT Hacking Medicine, ... Center for Innovation, today announced the five finalists ... Hackathon for Lyme disease.  More than 100 scientists, ...
Breaking Medicine Technology: